new drug for Parkinson's disease called Azilect (rasagiline)

Health Canada has approved a new drug for Parkinson's disease called Azilect (rasagiline).

It's an MAO-B inhibitor...similar to selegiline. It works by blocking the breakdown of dopamine.

Azilect can be used as initial therapy...to improve symptoms in patients with early Parkinson's.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote